Wire Stories
OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment
SUWON, South Korea–(BUSINESS WIRE)–#KOSDAQ226950—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company presented its latest...